Laura Esserman
University of California, San Fancisco - Department of Surgery · University of California, San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
7
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
NIH RePORTER
Trial papers
70
PubMed author-name match
Trials
Studies that name Laura Esserman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06075953 · DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentQuantumLeap Healthcare Collaborative · recruiting · Ductal Carcinoma in Situ · principal investigator
- Ph2NCT04488081 · I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsQuantumLeap Healthcare Collaborative · active not recruiting · COVID-19 · principal investigator
- Early Ph1NCT02872025 · Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)Laura Esserman · active not recruiting · Carcinoma, Intraductal, Noninfiltrating · principal investigator
- N/ANCT02620852 · Women Informed to Screen Depending on Measures of Risk (Wisdom Study)University of California, San Francisco · recruiting · Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer · principal investigator
- Ph4NCT01258296 · Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap ReconstructionUniversity of California, San Francisco · completed · Postoperative Pain After Breast Reconstruction With Abdominal Flap · principal investigator
- Ph2NCT01042379 · I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerQuantumLeap Healthcare Collaborative · recruiting · Breast Neoplasms, Breast Cancer, Breast Tumors · principal investigator
- Ph1NCT00788112 · Vorinostat in Treating Women With Ductal Carcinoma in Situ of the BreastUniversity of California, San Francisco · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Core 3: Communications, Administrations, Advocacy, and Project ManagementP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2017 to 2026 · $252,601 awarded in 2026Same name and institution; not confirmed by an ID
- Project 1: Implementing Risk-based Tools that Incorporate Tumor Biology to Optimize Screening and PreventionP01CA281826 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2024 to 2026 · $854,215 awarded in 2026Same name and institution; not confirmed by an ID
- RISE UP for Breast Cancer 2026R13CA310705 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2026 · $12,500 awarded in 2026Same name and institution; not confirmed by an ID
- Extending the Diversity, Reach, and Generalizability of the WISDOM StudyR01CA237533 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2020 to 2024 · $1,741,554 awarded in 2024Grant number is on one of their registry trials
- RISE UP for Breast CancerR13CA294950 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2024 · $7,000 awarded in 2024Same name and institution; not confirmed by an ID
- Surgical Oncology Training GrantT32CA251070 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2020 to 2024 · $355,791 awarded in 2024Same name and institution; not confirmed by an ID
- Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancersU01CA196406 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2015 to 2020 · $654,899 awarded in 2020Same name and institution; not confirmed by an ID
- Modeling the Impact of Targeted Therapy Based on Breast Cancer SubtypesU01CA187945 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2014 to 2018 · $504,776 awarded in 2018Same name and institution; not confirmed by an ID
- Integrated Biomarkers to Characterize Breast Cancer RiskU01CA111234 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2004 to 2009 · $555,114 awarded in 2009Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:33 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- 632 citationsRCR 21.1
- 620 citationsRCR 24.3
- 564 citationsRCR 16.2
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med · 2016456 citationsRCR 12.7
- 435 citationsRCR 10.1
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell · 2021307 citationsRCR 13.7
- Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med · 2016296 citationsRCR 7.8
- 275 citationsRCR 7.9
- Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.Radiology · 2018231 citationsRCR 9.9
- 195 citationsRCR 7.5